Nuveen Asset Management LLC Purchases 217,199 Shares of Myokardia Inc (NASDAQ:MYOK)

Nuveen Asset Management LLC raised its position in shares of Myokardia Inc (NASDAQ:MYOK) by 2,581.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 225,613 shares of the biotechnology company’s stock after acquiring an additional 217,199 shares during the quarter. Nuveen Asset Management LLC’s holdings in Myokardia were worth $11,312,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of MYOK. New York State Common Retirement Fund lifted its holdings in shares of Myokardia by 9.6% during the first quarter. New York State Common Retirement Fund now owns 41,418 shares of the biotechnology company’s stock valued at $2,153,000 after purchasing an additional 3,614 shares during the last quarter. Trexquant Investment LP purchased a new stake in Myokardia during the 1st quarter valued at $1,610,000. Marshall Wace LLP purchased a new stake in Myokardia during the 1st quarter valued at $23,678,000. Marshall Wace North America L.P. raised its stake in Myokardia by 5,541.2% during the 1st quarter. Marshall Wace North America L.P. now owns 252,612 shares of the biotechnology company’s stock valued at $13,133,000 after buying an additional 248,134 shares during the last quarter. Finally, FMR LLC grew its position in shares of Myokardia by 12.4% during the 1st quarter. FMR LLC now owns 6,786,728 shares of the biotechnology company’s stock valued at $352,842,000 after acquiring an additional 746,122 shares during the period.

A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Myokardia from a “buy” rating to a “hold” rating in a research report on Thursday, September 26th. ValuEngine cut shares of Myokardia from a “strong-buy” rating to a “buy” rating in a report on Thursday. Wedbush raised their target price on shares of Myokardia from $87.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Zacks Investment Research upgraded shares of Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Finally, Guggenheim started coverage on shares of Myokardia in a research report on Thursday, September 19th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Myokardia has a consensus rating of “Buy” and a consensus price target of $76.89.

In related news, insider Jake Bauer sold 19,700 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $60.09, for a total transaction of $1,183,773.00. Following the transaction, the insider now directly owns 76,068 shares in the company, valued at $4,570,926.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anastasios Gianakakos sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $52.28, for a total transaction of $209,120.00. Following the transaction, the chief executive officer now owns 100,770 shares in the company, valued at $5,268,255.60. The disclosure for this sale can be found here. Insiders have sold 57,751 shares of company stock worth $3,326,603 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Shares of NASDAQ MYOK opened at $53.55 on Friday. The company’s 50-day simple moving average is $53.86 and its 200-day simple moving average is $51.20. Myokardia Inc has a 52-week low of $39.01 and a 52-week high of $64.40. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -30.43 and a beta of 2.05.

Myokardia (NASDAQ:MYOK) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). Equities analysts expect that Myokardia Inc will post -4.32 EPS for the current fiscal year.

Myokardia Company Profile

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

Recommended Story: Momentum Investing

Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myokardia Inc (NASDAQ:MYOK).

Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.